The antigen CD300e drives T cell inflammation in adipose tissue and elicits an antibody response predictive of the insulin sensitivity recovery in obese patients.
Antibodies
Inflammation
Insulin resistance
Obesity
T cell response
Journal
Journal of inflammation (London, England)
ISSN: 1476-9255
Titre abrégé: J Inflamm (Lond)
Pays: England
ID NLM: 101232234
Informations de publication
Date de publication:
22 Nov 2022
22 Nov 2022
Historique:
received:
02
08
2022
accepted:
04
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
Obesity and insulin resistance (IR), the key features of metabolic syndrome, are closely associated with a state of chronic, low-grade inflammation. Bariatric surgery leads to a considerable reduction in the adipose tissue mass and systemic inflammation along with a reduction of IR, with a whole-body metabolic improvement. However, a sizable portion of people experience an IR relapse within few years of remission.Numerous studies have attempted to explore the best clinical predictors of the improvement of insulin sensitivity and the maintenance of glucose homeostasis after bariatric surgery, but no simple fasting blood test has been found to be effective in predicting the short and long-term beneficial effects on glycaemia.With the present study, we investigated T-cell and antibody responses against CD300e, an antigen highly expressed in the adipose tissue of patients with obesity before the bariatric surgery-induced weight loss. We found both in fat tissue and in peripheral blood anti-CD300e-specific T helper 1 responses. Moreover, we evidenced in the sera of individuals with obesity an antibody response towards CD300e and revealed the existence of a significant correlation between the level of antibodies before surgery and the maintenance of glucose control after the intervention.
Identifiants
pubmed: 36419085
doi: 10.1186/s12950-022-00318-7
pii: 10.1186/s12950-022-00318-7
pmc: PMC9682732
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2011 May;17(5):610-7
pubmed: 21499269
J Biol Chem. 2009 Nov 13;284(46):31936-44
pubmed: 19776010
Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1304-10
pubmed: 18420999
Immunol Rev. 2020 May;295(1):5-14
pubmed: 32320073
PLoS One. 2016 Aug 11;11(8):e0160576
pubmed: 27513516
J Clin Endocrinol Metab. 2021 Apr 23;106(5):1312-1324
pubmed: 33560372
Front Endocrinol (Lausanne). 2021 Sep 06;12:706978
pubmed: 34552557
J Immunol. 1997 Jan 15;158(2):962-7
pubmed: 8993017
Cell Metab. 2013 Mar 5;17(3):411-22
pubmed: 23473035
Circ Res. 2008 Aug 29;103(5):467-76
pubmed: 18658050
Sci Rep. 2020 Oct 5;10(1):16501
pubmed: 33020563
Rev Endocr Metab Disord. 2018 Dec;19(4):283-292
pubmed: 29922964
Cell Rep Med. 2021 Mar 30;2(4):100226
pubmed: 33948567
J Innate Immun. 2022;14(1):4-30
pubmed: 33849008
Haematologica. 2019 Dec;104(12):2519-2527
pubmed: 30872365
J Immunol. 2004 Dec 1;173(11):6703-11
pubmed: 15557162
Front Immunol. 2019 Jul 17;10:1587
pubmed: 31379820
Int J Obes (Lond). 2015 Nov;39(11):1607-18
pubmed: 26041698
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825